Company

Immunovant, Inc.

Headquarters: New York, NY, United States

Employees: 68

CEO: Dr. Peter Salzmann M.B.A., M.D.

NASDAQ: IMVT -7.08%

Market Cap

$3.96 Billion

USD as of Jan. 1, 2025

Market Cap History

Immunovant, Inc. market capitalization over time

Evolution of Immunovant, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Immunovant, Inc.

Detailed Description

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

Top 1-year algo backtest: +327.04%

$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Financials

Last Financial Reports Date Sept. 30, 2024
Revenue TTM $0
EBITDA $-352,164,992
Gross Profit TTM $0
Profit Margin 0.00%
Operating Margin 0.00%
Quarterly Revenue Growth %
Financial Reports & Statistics

Stocks & Indices

Immunovant, Inc. has the following listings and related stock indices.


Stock: NASDAQ: IMVT wb_incandescent

Details

Headquarters:

320 West 37th Street

New York, NY 10018

United States

Phone: 917 580 3099